Sanofi Ends SAR448272 Trial, Nurix Shares Update
Nurix Therapeutics says Sanofi has discontinued the Phase 1 trial of its oral STAT6 degrader SAR448272 and terminated the program.
Updated on Nov. 3, 2026 in Biotech
Sanofi notified Nurix Therapeutics that it is discontinuing the Phase 1 first-in-human trial of SAR448272, an oral STAT6 degrader, and terminating the program. Nurix does not anticipate receiving future development, regulatory, or commercial milestone payments for the program.
Why it matters
The decision removes a program from a collaboration that Nurix had built on its DEL-AI drug discovery platform, which uses E3 ligases to induce protein degradation. Nurix remains eligible for milestones and royalties on other licensed programs under the same agreement.
Nurix's DEL-AI platform is built to identify agents that use E3 ligases to induce protein degradation under the 2019 collaboration with Sanofi. The discontinued candidate, SAR448272, is an oral STAT6 degrader in Phase 1 development.
The players
Nurix Therapeutics
Nurix Therapeutics is a Brisbane, California biotechnology company developing targeted protein degradation medicines using its DEL-AI discovery platform.
Sanofi
Sanofi is a global pharmaceutical company headquartered in Paris that partnered with Nurix on the STAT6 degrader program.
The details
Sanofi notified Nurix of its decision to end the first-in-human trial of SAR448272 and terminate the program. Nurix says it still holds eligibility for milestones and royalties on other licensed programs, while Sanofi may further develop other previously announced candidates at its discretion.
Timeline
2019: Nurix and Sanofi signed their collaboration agreement.
2025: Sanofi exercised a license extension option for two programs.
November 3, 2026: Nurix announced the SAR448272 discontinuation.
Market Landscape
Nurix's E3 ligase degrader approach places it among companies advancing targeted protein degradation as an alternative to conventional small-molecule inhibitors. The loss of one STAT6 candidate shows how early-stage programs in this field can be discontinued even as others advance, including bexobrutideg in Phase 3 for chronic lymphocytic leukemia.
For people with conditions that STAT6 signaling may influence, this development means one candidate is no longer advancing, so no near-term treatment from this program should be expected. Other Nurix programs, including bexobrutideg in Phase 3 for chronic lymphocytic leukemia, remain in development.
The takeaway
Early-stage drug programs can be discontinued even within well-funded partnerships, so investors and patients should track clinical milestones rather than pipeline announcements alone. Nurix's runway into the second half of 2029 gives its remaining programs time to reach the next data readouts.
What happens next
Nurix has said it could receive milestone payments and royalties on other licensed programs, and Sanofi retains discretion over further development of previously announced candidates; no specific dates for those steps are given in the source.
Further reading
For more on the research behind this decision, explore Biotech coverage on Wisevoter.
